Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Invitae Corp NVTAQ

Healthcare
Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services, digital health solutions, and health data services that support a lifetime of patient care and improved outcomes. It offers genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. It applies... see more

Recent & Breaking News (GREY:NVTAQ)

Labcorp Finalizes Acquisition of Select Assets of Invitae

PR Newswire August 5, 2024

Labcorp Announces Winning Bid for Select Assets of Invitae

PR Newswire April 24, 2024

Invitae Enters into Agreement with Labcorp for Sale of Business

PR Newswire April 24, 2024

Invitae Publishes its Environmental, Social and Governance (ESG) Report

PR Newswire April 22, 2024

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

PR Newswire April 11, 2024

Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process

PR Newswire February 13, 2024

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

PR Newswire January 30, 2024

Invitae Completes Sale of Reproductive Health Assets to Natera

PR Newswire January 22, 2024

Invitae Divests Ciitizen Health Data Platform and Implements Further Cost Cuts

PR Newswire December 13, 2023

Invitae Reports Third Quarter 2023 Financial Results

PR Newswire November 8, 2023

Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships

PR Newswire November 6, 2023

Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

PR Newswire November 1, 2023

Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results

PR Newswire October 25, 2023

Invitae Appoints Dr. David Sholehvar as Chief Operating Officer

PR Newswire October 19, 2023

Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer

PR Newswire October 12, 2023

Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics

PR Newswire October 10, 2023

Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization

PR Newswire October 3, 2023

Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO

PR Newswire September 25, 2023

Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard

PR Newswire September 22, 2023

Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer

PR Newswire August 28, 2023